Concepedia

Roz Brant

RB

Statistics

Publications

4

Citations

562

H-Index

4

Active since

2015

Affiliations

AstraZeneca (United Kingdom)(Current)

AstraZeneca (United States)

The Christie NHS Foundation Trust

Roz Brant is an author at AstraZeneca (United Kingdom) specializing in oncology, molecular oncology, and medicine.

Publications per year

2015–2019

4

Publications

4

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

Kenneth S. Thress, Roz Brant, T. Hedley Carr et al. · Lung Cancer · 2015 · 493 citations · Full text

Medicine, Oncology, Pharmacology +17

Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma

Avinash Gupta, Christopher Towers, Frances Willenbrock et al. · British Journal of Cancer · 2019 · 30 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors

Roz Brant, Alan Sharpe, Tom Liptrot et al. · Clinical Cancer Research · 2016 · 28 citations

Medicine, Bioinformatics, Oncology +17

Correlation between MEK signature and Ras gene alteration in advanced gastric cancer

Soomin Ahn, Roz Brant, Alan Sharpe et al. · Oncotarget · 2017 · 11 citations · Full text

Medicine, Genetics, Oncology +17

1–4 of 4